Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease

References

• Ahmed AM, Ghany MA, Hakeem GLA, et al. Assessment of vitamin D status in a group of Egyptian children with nonalcoholic fatty liver disease. Nutr Metab. 2016;13(1):1–6.
   Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res. 2017;8(4):343–349. doi:10.1016/j.jare.2017.03.004
   Web of Science ®Google Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver dis- ease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–1832. doi:10.1002/hep.23594
   PubMed Web of Science ®Google Scholar
• Mohamed AA, Ahmed HH, ElSadek SM, et al. A study of leptin and its gene 2548 G/A Rs7799039 single-nucleotide polymorphisms in Egyptian children, a single-center experience. Clin Res Hepatol Gastroenterol. 2021;45:101724. doi:10.1016/j.clinre.2021.101724
   Web of Science ®Google Scholar
• Ferreira DM, Simao AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 2014;281(11):2503–2524. doi:10.1111/febs.12806
   Web of Science ®Google Scholar
• Arab JP, Barrera F, Arrese M. The evolving role of liver biopsy in non-alcoholic fatty liver disease. Ann Hepatol. 2018;17(6):899–902. doi:10.5604/01.3001.0012.7188
   PubMed Web of Science ®Google Scholar
• Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotechnol. 2010;2(4):161–179.
   PubMedGoogle Scholar
• Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862–864. doi:10.1126/science.1065329
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355. doi:10.1038/nature02871
   PubMed Web of Science ®Google Scholar
• Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–859. doi:10.4161/rna.20378
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812; PMID: 24973316; PMCID: PMC4277726. doi: 10.1136/gutjnl-2014-306996
   PubMed Web of Science ®Google Scholar
• Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the tran- sition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. doi:10.1155/2014/741465
   Web of Science ®Google Scholar
• Goedert M, Emson PC. The regional distribution of neurotensin like immunoreactivity in central and peripheral tissues of the cat. Brain Res. 1983;272(2):291–297. doi:10.1016/0006-8993(83)90576-0
   Web of Science ®Google Scholar
• Ferris CF, Hammer RA, Leeman SE. Elevation of plasma neurotensin during lipid perfusion of rat small intestine. Peptides. 1981;2(Suppl 2):263–266. doi:10.1016/0196-9781(81)90042-5
   Web of Science ®Google Scholar
• Leeman SE, Carraway RE. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann N Y Acad Sci. 1982;400(1):1–16. doi:10.1111/j.1749-6632.1982.tb31557.x
   Web of Science ®Google Scholar
• Gui X, Carraway RE. Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. Gastroenterology. 2001;120(1):151–160. doi:10.1053/gast.2001.20876
   Web of Science ®Google Scholar
• Gui X, Dobner PR, Carraway RE. Endogenous neurotensin facilitates enterohepatic bile acid circulation by enhancing intestinal uptake in rats. Am J Physiol Gastrointest Liver Physiol. 2001;281(6):G1413–G1422. doi:10.1152/ajpgi.2001.281.6.G1413
   Web of Science ®Google Scholar
• Li J, Song J, Zaytseva YY, et al. An obligatory role for neurotensin in high-fat diet-induced obesity. Nature. 2016;533(7603):411–415. doi:10.1038/nature17662
   PubMed Web of Science ®Google Scholar
• Chen C, Tan R, Wong L, Fekete R, Halsey J. Quantitation of microRNAs by real-time RT-qPCR. In: Park DJ, editor. Vol. 687. Methods. Totowa, NJ: Humana Press; 2011:113–134. Doi:10.1007/978-1-60761-944-4_8
   Google Scholar
• Salvoza NC, Klinzing DC, Gopez-Cervantes J, Baclig MO. Association of circulating serum mi-RNA-34a and mi-RNA-122 with dyslipidemia among patients with non-alcoholic fatty liver disease. PLoS One. 2019;11(4):e0153497. doi:10.1371/journal
   Google Scholar
• Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6(8):e23937. doi:10.1371/journal.pone.0023937
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Latendresse JR, Montgomery B, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol. 2012;262(1):52–59. doi:10.1016/j.taap.2012.04.018
   PubMed Web of Science ®Google Scholar
• Becker PP, Rau M, Schmitt J, et al. Performance of serum microRNAs −122, −192 and −21 as biomarkers in patients with non-alcoholic Steatohepatitis. PLoS One. 2015;10:e0142661. doi:10.1371/journal.pone.0142661
   PubMed Web of Science ®Google Scholar
• Auguet T, Aragonès G, Berlanga A, et al. miR33a/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease. Int J Mol Sci. 2016;17:1620. doi:10.3390/ijms17101620
   Web of Science ®Google Scholar
• Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum mi-RNA-29a and mi-RNA- 122 as potential biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Microrna. 2018;7(3):215–222. doi:10.2174/2211536607666180531093302
   PubMedGoogle Scholar
• Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology. 2008;48(6):1810–1820. doi:10.1002/hep.22569
   PubMed Web of Science ®Google Scholar
• Waidmann O, Köberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One. 2012;7(9):e45652. doi:10.1371/journal.pone.0045652
   PubMed Web of Science ®Google Scholar
• Gao Y, He Y, Ding J, et al. An insertion/deletion polymorphism at miRNA-122 binding site in the interleukin-1a 3′untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30:2064–2069. doi:10.1093/carcin/bgp283
   PubMed Web of Science ®Google Scholar
• Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012;308(14):1469–1475. doi:10.1001/jama.2012.12998
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Lyass A, Liu Y, et al. Circulating proneurotensin concentrations and cardiovascular disease events in the community: the Framingham heart study. Arterioscler Thromb Vasc Biol. 2016;36(8):1692–1697; PMID: 27312221; PMCID: PMC4965295. doi: 10.1161/ATVBAHA.116.307847
   PubMed Web of Science ®Google Scholar
• Barchetta I, Cimini FA, Leonetti F, et al. Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes. J Clin Endocrinol Metab. 2018;103(6):2253–2260. PMID: 29590379. doi:10.1210/jc.2017-02751
   Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36. doi:10.1148/radiology.143.1.7063747
   PubMed Web of Science ®Google Scholar
• Abdelfattah AAM, Rizk F, Hawash N, Hanafy A, El-Kalla F, Abd-Elsalam S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int J Hyperthermia. 2018;34(8):1367–1371. doi:10.1080/02656736.2018.1424946
   PubMed Web of Science ®Google Scholar
• Wasfy E, Elkassas G, Elnawasany S, et al. Predicting esophageal varices in cirrhotic hepatitis C virus patients using noninvasive measurement of insulin resistance variables. Endocr Metab Immune Disord Drug Targets. 2018;18(6):573–580. PMID: 30073932. doi:10.2174/1871530318666180803120428
   Web of Science ®Google Scholar
• Mohamed AA, El-Toukhy NER, Said EM, et al. Hepatitis C virus: efficacy of new DAAs regimens. Infect Disord Drug Targets. 2020;20(2):143–149. PMID: 30663575. doi:10.2174/1871526519666190121114003
   Google Scholar
• Soliman H, Ziada D, Salama M, et al. Predictors for fibrosis regression in chronic HCV patients after the treatment with DAAS: results of a real-world cohort study. Endocr Metab Immune Disord Drug Targets. 2019;19:1–8. PMID: 31448717. doi:10.2174/187153031901181217112442
   Web of Science ®Google Scholar
• El-Gebaly F, Abou-Saif S, Elkadeem M, et al. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in Egyptian patients. Curr Cancer Drug Targets. 2019;19(11):896–905. doi:10.2174/1568009619666190718141647
   PubMed Web of Science ®Google Scholar
• Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res. 2017;11(2):OC32–OC34. doi:10.7860/JCDR/2017/23095.9450
   PubMed Web of Science ®Google Scholar